Abstract
10033 Background: Hormoneal therapy is one of the most common conservative approaches to desmoid-type fibromatosis (DF). Tamoxifene has been so far the preferred compound. Anecdotal cases treated by Toremifene (T) have also been described. Its mechanism of action is not completely understood, but a possible role in regulating the level of TGF-β and its receptors has been suggested. Aim of the study was to further investigate the feasibility and activity of T in DF. Methods: All consecutive patients affected by sporadic DF, either primarily or secondarily treated with T on a named basis, were prospectively collected. Indication for therapy were either progressive disease and/or pain. Drug schedule was 180 mg daily, until progression or toxicity. Disease assessment was performed by contrast-enhanced MRI or CT scan, pain evaluation by a visual analog scale (VAS) every 3 months. Response was evaluated either by RECIST and/or symptomatic relief. Results: Between 2008 and 2010, 27 patients (F/M ratio = 2.9) wer...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
